APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Outlook and Growth Opportunities 2026

Report ID 173982180430 December 2025195 pages

Choose your research edition.

Industry ResearchCytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market include CSL, Biotest, Beijing Tiantan Biological Products, Shanxi Kangbao Biological Product and Taibang Biologic Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market size, projected growth trends, production technologies, key applications, and end-use industries.

Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Company

CSL

Biotest

Beijing Tiantan Biological Products

Shanxi Kangbao Biological Product

Taibang Biologic Group

Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Type

25ml

50ml

100ml

Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Application

Hopistial

Clinic

Others

Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) significant trends, drivers, influence factors in global and regions.

6. To analyze Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) industry.

Chapter 3: Detailed analysis of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Trends Table 2. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Drivers Table 3. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Opportunities and Challenges Table 4. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Restraints Table 5. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Share by Company (2021-2026) Table 7. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Company (Units) & (2021-2026) Table 8. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Company (2021-2026) Table 9. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Key Company Manufacturing Base & Headquarters Table 12. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company, Product Type & Application Table 13. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 25ml Table 18. Significant Companies of 50ml Table 19. Significant Companies of 100ml Table 20. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type (2021-2026) & (Units) Table 22. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type (2027-2032) & (Units) Table 23. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Type (2021-2026) Table 24. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Type (2027-2032) Table 25. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type (2021-2026) Table 29. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hopistial Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 34. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application (2021-2026) & (Units) Table 35. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application (2027-2032) & (Units) Table 36. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Application (2021-2026) Table 37. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Application (2027-2032) Table 38. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application (2021-2026) Table 42. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application (2027-2032) Table 43. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 44. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region (2021-2026) & (Units) Table 45. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Region (2021-2026) Table 46. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region (2027-2032) & (Units) Table 47. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Region (2027-2032) Table 48. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Region (2021-2026) Table 51. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Region (2027-2032) Table 53. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 56. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2026) & (Units) Table 58. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Country (2021-2026) Table 59. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2027-2032) & (Units) Table 60. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Country (2027-2032) Table 61. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Market Share by Country (2021-2026) Table 63. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Market Share by Country (2027-2032) Table 65. CSL Company Information Table 66. CSL Business Overview Table 67. CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio Table 69. CSL Recent Development Table 70. Biotest Company Information Table 71. Biotest Business Overview Table 72. Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio Table 74. Biotest Recent Development Table 75. Beijing Tiantan Biological Products Company Information Table 76. Beijing Tiantan Biological Products Business Overview Table 77. Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio Table 79. Beijing Tiantan Biological Products Recent Development Table 80. Shanxi Kangbao Biological Product Company Information Table 81. Shanxi Kangbao Biological Product Business Overview Table 82. Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio Table 84. Shanxi Kangbao Biological Product Recent Development Table 85. Taibang Biologic Group Company Information Table 86. Taibang Biologic Group Business Overview Table 87. Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio Table 89. Taibang Biologic Group Recent Development Table 90. Key Raw Materials Table 91. Raw Materials Key Suppliers Table 92. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Distributors List Table 93. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Customers List Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Image Figure 2. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales (2021-2032) & (Units) Figure 5. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 25ml Image Figure 10. 50ml Image Figure 11. 100ml Image Figure 12. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Type (2021-2032) Figure 15. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type (2021-2032) Figure 18. Hopistial Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 22. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Application (2021-2032) Figure 24. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application (2021-2032) Figure 27. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 28. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 25ml
  • 50ml
  • 100ml
Applications
  • Hopistial
  • Clinic
  • Others
Companies covered
  • CSL
  • Biotest
  • Beijing Tiantan Biological Products
  • Shanxi Kangbao Biological Product
  • Taibang Biologic Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032)
  4. 1.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume (2021-2032)
  5. 1.2.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Dynamics
  1. 2.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Trends
  2. 2.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Drivers
  3. 2.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Opportunities and Challenges
  4. 2.4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Restraints
3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Company
  1. 3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Revenue Ranking in 2025
  2. 3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Company (2021-2026)
  3. 3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Company (2021-2026)
  4. 3.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Average Price by Company (2021-2026)
  5. 3.5 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Ranking (2024-2026)
  6. 3.6 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Manufacturing Base and Headquarters
  7. 3.7 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Product Type and Application
  8. 3.8 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Type
  1. 4.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Type Introduction
  2. 4.1.1 25ml
  3. 4.1.2 50ml
  4. 4.1.3 100ml
  5. 4.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type
  6. 4.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type
  10. 4.3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Type (2021-2032)
  12. 4.3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type (2021-2032)
5 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Application
  1. 5.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Application Introduction
  2. 5.1.1 Hopistial
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application
  6. 5.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application
  10. 5.3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application (2021-2032)
6 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Regional Sales and Value Analysis
  1. 6.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region (2021-2032)
  3. 6.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021-2026
  4. 6.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region (2027-2032)
  5. 6.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Region (2027-2032)
  9. 6.5 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032)
  12. 6.6.2 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032)
  15. 6.7.2 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032)
  21. 6.9.2 South America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Country, 2025 VS 2032
7 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Country-level Sales and Value Analysis
  1. 7.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
  4. 7.3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2026)
  5. 7.3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2027-2032)
  6. 7.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 Biotest
  8. 8.2.1 Biotest Company Information
  9. 8.2.2 Biotest Business Overview
  10. 8.2.3 Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
  12. 8.2.5 Biotest Recent Developments
  13. 8.3 Beijing Tiantan Biological Products
  14. 8.3.1 Beijing Tiantan Biological Products Company Information
  15. 8.3.2 Beijing Tiantan Biological Products Business Overview
  16. 8.3.3 Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
  18. 8.3.5 Beijing Tiantan Biological Products Recent Developments
  19. 8.4 Shanxi Kangbao Biological Product
  20. 8.4.1 Shanxi Kangbao Biological Product Company Information
  21. 8.4.2 Shanxi Kangbao Biological Product Business Overview
  22. 8.4.3 Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
  24. 8.4.5 Shanxi Kangbao Biological Product Recent Developments
  25. 8.5 Taibang Biologic Group
  26. 8.5.1 Taibang Biologic Group Company Information
  27. 8.5.2 Taibang Biologic Group Business Overview
  28. 8.5.3 Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
  30. 8.5.5 Taibang Biologic Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Value Chain Analysis
  2. 9.1.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Mode & Process
  6. 9.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Distributors
  9. 9.2.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst